Enhancing the Pharmacokinetic Profile of Protein-based Drugs

Award Information
Agency: Department of Defense
Branch: Office for Chemical and Biological Defense
Contract: W911NF-14-C-0071
Agency Tracking Number: C2-0391
Amount: $999,998.00
Phase: Phase II
Program: SBIR
Solicitation Topic Code: CBD12-101
Solicitation Number: 2012.2
Timeline
Solicitation Year: 2012
Award Year: 2014
Award Start Date (Proposal Award Date): 2015-05-21
Award End Date (Contract End Date): 2016-06-25
Small Business Information
1 Kendall Sq. Bldg. 200, Suite 2203, Cambridge, MA, 02139
DUNS: 000000000
HUBZone Owned: N
Woman Owned: Y
Socially and Economically Disadvantaged: N
Principal Investigator
 Laura Hales, Ph.D.
 Founder, Chief Business O
 (732) 599-8581
 lhales@extendbio.com
Business Contact
 Tarik Soliman, Ph.D.
Title: Founder, Chief Executive
Phone: (732) 599-8580
Email: tsoliman@extendbio.com
Research Institution
N/A
Abstract
Many protein-based drugs have limited efficacy due to a short half-life or require intravenous delivery because of low bioavailability. Extend Biosciences is developing proprietary carrier molecules that allow proteins to access an intrinsic transport pathway for efficient delivery to the vascular space and then maintain a sustained presence in circulation. This novel technology would be of particular importance in the development of longer-lasting versions of bioscavenger proteins that could then be delivered subcutaneously or intramuscularly and become bioavailable within minutes of administration. In this project, one of Extend Biosciences carrier molecules will be conjugated to two bioscavenger proteins of interest to the military. The modified bioscavengers will be tested for their improved half-life and rapid bioavailability in an appropriate animal model. Safety of the modified proteins will be assessed by testing whether the modified proteins induce toxicity or an immune response. A successful project will enable the prophylactic or acute on-site treatment options to counteract the threat of intoxication and death by organophosphate compounds. This project will demonstrate the feasibility of improving the half-life and bioavailability of bioscavenger proteins that could be applied to numerous other protein-based drugs including those used in Chemical and Biological Defense treatments.

* Information listed above is at the time of submission. *

Agency Micro-sites

SBA logo
Department of Agriculture logo
Department of Commerce logo
Department of Defense logo
Department of Education logo
Department of Energy logo
Department of Health and Human Services logo
Department of Homeland Security logo
Department of Transportation logo
Environmental Protection Agency logo
National Aeronautics and Space Administration logo
National Science Foundation logo
US Flag An Official Website of the United States Government